Thermo Fisher Scientific has launched a new pharmacogenetic test called TacroType, designed to personalize tacrolimus dosing for transplant patients based on their genetic profile. This product targets transplant centers and clinicians managing post-transplant medication. The company is a major provider in the life sciences tools and diagnostics sector. The announcement was made as the company's shares were noted to be trading below their target prices.